244 related articles for article (PubMed ID: 21543518)
1. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
Davis MB; Vasquez-Dunddel D; Fu J; Albesiano E; Pardoll D; Kim YJ
Clin Cancer Res; 2011 Jun; 17(12):3984-92. PubMed ID: 21543518
[TBL] [Abstract][Full Text] [Related]
2. A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.
Xiao L; Kim J; Lim M; Dai B; Yang L; Reed SG; Baltimore D; Wang P
Vaccine; 2012 Mar; 30(15):2570-81. PubMed ID: 22314134
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
[TBL] [Abstract][Full Text] [Related]
4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
5. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
Yang SC; Hillinger S; Riedl K; Zhang L; Zhu L; Huang M; Atianzar K; Kuo BY; Gardner B; Batra RK; Strieter RM; Dubinett SM; Sharma S
Clin Cancer Res; 2004 Apr; 10(8):2891-901. PubMed ID: 15102698
[TBL] [Abstract][Full Text] [Related]
8. Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.
Park SN; Noh KT; Jeong YI; Jung ID; Kang HK; Cha GS; Lee SJ; Seo JK; Kang DH; Hwang TH; Lee EK; Kwon B; Park YM
Exp Mol Med; 2013 Feb; 45(2):e8. PubMed ID: 23392255
[TBL] [Abstract][Full Text] [Related]
9. Campylobacter jejuni-induced activation of dendritic cells involves cooperative signaling through Toll-like receptor 4 (TLR4)-MyD88 and TLR4-TRIF axes.
Rathinam VA; Appledorn DM; Hoag KA; Amalfitano A; Mansfield LS
Infect Immun; 2009 Jun; 77(6):2499-507. PubMed ID: 19332531
[TBL] [Abstract][Full Text] [Related]
10. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
[TBL] [Abstract][Full Text] [Related]
11. PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF.
Goyal G; Wong K; Nirschl CJ; Souders N; Neuberg D; Anandasabapathy N; Dranoff G
Cancer Immunol Res; 2018 Jun; 6(6):723-732. PubMed ID: 29669721
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
13. Murine mammary carcinoma cells and CD11c(+) dendritic cells elicit distinct responses to lipopolysaccharide and exhibit differential expression of genes required for TLR4 signaling.
Palha De Sousa C; Blum CM; Sgroe EP; Crespo AM; Kurt RA
Cell Immunol; 2010; 266(1):67-75. PubMed ID: 20869044
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant effect of lipopolysaccharide on the induction of contact hypersensitivity to haptens in mice.
Yokoi S; Niizeki H; Iida H; Asada H; Miyagawa S
J Dermatol Sci; 2009 Feb; 53(2):120-8. PubMed ID: 18829266
[TBL] [Abstract][Full Text] [Related]
15. [Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine].
Wang Z; You H; Song S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Apr; 29(4):379-83. PubMed ID: 23643168
[TBL] [Abstract][Full Text] [Related]
16. Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines.
Ali OA; Doherty E; Mooney DJ; Emerich D
Biomatter; 2011; 1(1):66-75. PubMed ID: 23507728
[TBL] [Abstract][Full Text] [Related]
17. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
18. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
19. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
